The research hypothesizes that CTE can modulate key biomarkers involved in Parkinson’s pathology, including α-synuclein, interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α), assessed through qRT-PCR, as well as interleukin-6 (IL-6) and TNF-α, evaluated through ELISA. The gene discussed is IL6; the disease is Parkinson disease.